CEPI – Coalition for Epidemic Preparedness Innovations [to 9 September 2017]
Call: Platform technologies to enable rapid vaccine development for epidemic prone infections
CEPI is pleased to announce its second funding opportunity for the development of vaccines against epidemic infectious diseases.
In this two-step call, CEPI asks for submission of proposals for vaccine platform technologies that enable rapid vaccine development, rapid scale up, and quick time to immunity for reactive use in outbreaks of novel or previously unrecognised viruses. Proposals can include new platforms with the potential for rapidly making a vaccine using materials generally regarded as safe (GRAS), or those compressing the time of an existing (proven) platform to make it more responsive in an unknown threat situation. During the proposed project period, we encourage developers to target the following timelines:
Target a 16-week timeframe from identification of antigen to product release for clinical trials
Target a 6-week timeframe from administration of first dose to achievement of clinical benefit (i.e. immune response likely to result in clinical benefit)
Produce 100,000 vaccine doses within 8 weeks to impact an emerging outbreak (i.e. from Go-decision to scale-up to production, fill, finish, and release)
Deadline for submission of step 1 proposals: 4 p.m. CEST 17 October 2017
Call text for proposals on platform technology PDF FORMAT – 272KB Download
EDCTP [to 9 September 2017]
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
No new digest content identified.
European Medicines Agency [to 9 September 2017]
Reporting side effects of medicines
EMA launches survey to assess whether patients and doctors are aware of the arrangements for reporting of side effects …
FDA [to 9 September 2017]
What’s New in Biologics
Influenza Virus Vaccine for the 2017-2018 Season
Fondation Merieux [to 9 September 2017]
September 5, 2017, Bamako, Mali
First day of school for the BAMS training in medical applied biology
On 1 October 2007[?2017?], the first year of students – professionals of biological analysis, arrived at the Charles Mérieux Center for Infectious Disease in Bamako in order to follow the new qualified laboratory technicians training: BAMS.
The Mérieux Foundation knows that the improvement of the quality in public health needs the strengthening of capacities in medical biology: it has decided, in partnership with ESTBB, to create the BAMS training.
16 laboratory technicians selected among 85 candidates will follow until May 2008 theoretical and practical teaching in the fields of immunology, biochemistry, bacteriology, parasitology, virology and molecular biology. The teachers of these courses are Malian and French.
The technicians chosen for this first year of BAMS work in different national health centres of reference in Mali and Burkina Faso. The Ministry of Health in Mali accepted that the technicians follow the training because the health professionals were committed to return to work in their original laboratories in order to contribute to the quality of the public health.
Gavi [to 9 September 2017]
05 September 2017
Sierra Leone to begin cholera vaccination drive in disaster-affected areas
More than 1 million doses of Gavi-funded cholera vaccines heading to Sierra Leone after severe flooding and landslides.
[See Cholera above for more detail]
IVI [to 9 September 2017]
September 4, 2017
IVI Hosts 17th International Vaccinology Course in Seoul on September 4-8
:: Aeras Chief Medical Officer Dr. Ann Ginsberg delivers closing plenary speech on TB vaccine development; Korea University Prof. Woo-joo Kim to address Vaccine Preparedness and Response to Emerging Infectious Diseases
:: 112 participants from 19 countries including trainees participate in this year’s event hosted jointly by IVI, KOHI
:: 35 experts from international agencies, research institutions, universities, industry and non-profit organizations, including IVI, WHO and U.S. NIH serve as faculty members
MSF/Médecins Sans Frontières [to 9 September 2017]
Nigeria: MSF Scales Up Efforts to Contain Cholera Outbreak in Maiduguri
September 01, 2017
NEW YORK/MAIDUGURI, NIGERIA, SEPTEMBER 1, 2017—The international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) is scaling up treatment and prevention to curb the spread of cholera in Maiduguri in Borno State, Nigeria.
NIH [to 9 September 2017]
September 7, 2017
NIH awards nearly $100 million for Autism Centers of Excellence program
— Program supports large research projects aimed at understanding and developing interventions for autism spectrum disorder
NCI’s Douglas R. Lowy and John T. Schiller to receive 2017 Lasker Award
September 6, 2017 — Scientists honored for their research leading to the development of HPV vaccines
[See Milestones above for more detail]
Zika virus selectively infects and kills glioblastoma cells in mice
September 5, 2017 — Researchers describe the impact of ZIKV on glioblastoma cells in human tissue samples and mice
Drug combination reduces risk of HIV infection among teen males
September 5, 2017 — NIH-funded study suggests PrEP therapy, approved for adults, is safe for youth.
PATH [to 9 September 2017]
Press release | September 08, 2017
PATH and Walter Reed Army Institute of Research announce largest-ever controlled malaria infection study
Study in adult US volunteers to investigate which changes in the RTS,S malaria vaccine candidate regimen increase protection the most
Press release | September 06, 2017
PATH boosts leadership in developing and introducing urgently needed vaccines
PATH’s Center for Vaccine Innovation and Access attracts top global talent and additional $120 million investment from the Bill & Melinda Gates Foundation
[See Milestones above for more detail]
Wellcome Trust [to 9 September 2017]
News / Published: 4 September 2017
Wellcome joins £52 million global drive on antibiotic resistance
Wellcome is committing up to £1 million as part of a £52 million (€56.5m) global pledge to tackle antibiotic resistance.
Latest funding for the Global Antibiotic Research and Development Partnership (opens in a new tab) (GARDP) was announced today by the German government.
Other countries and foundations pledging funds include the Netherlands, Switzerland, South Africa, Luxembourg and the UK government.
Jeremy Farrar, Wellcome’s Director, said: “We must all work together to address the deadly threat of drug-resistant infections, which already kill 700,000 people a year. Wellcome is delighted to work with Germany and other partners to ensure communities around the world are better protected against this and other serious health threats.”…
DCVMN – Developing Country Vaccine Manufacturers Network [to 9 September 2017]
25 September 2017 to 28 September 2017
DCVMN Annual General Meeting
Seoul / Korea